DBVT
DBVT clinical trials: DBV Technologies S.A.
Every trial on ClinicalTrials.gov where DBV Technologies S.A. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 16
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
DBVT on the catalyst calendar · DBVT registry changes
- Primary completion May 13, 2025ActualPhase 3NCT03859700Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young ChildrenDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2017ActualPhase 3NCT02916446Safety Study of Viaskin Peanut to Treat Peanut AllergyDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 3NCT07003919Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)DBV Technologies · AllergyActive, not recruitingDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 6, 2025ActualPhase 3NCT05741476Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgeDBV Technologies · Allergy, PeanutActive, not recruitingDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05424731Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic ChildrenDBV Technologies · Peanut AllergyAvailableDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2017ActualPhase 3NCT02636699Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut AllergyDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2019ActualPhase 3NCT03211247Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of AgeDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2017ActualPhase 1/Phase 2NCT02223182Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk AllergyDBV Technologies · Food AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2024Sponsor estimatePhase 2NCT04492683Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in ChildrenDBV Technologies · Cow's Milk AllergyUnknown statusDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016ActualPhase 2NCT01955109Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and ChildrenDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 2NCT01675882Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut AllergyDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04371627Viaskin® Peanut (DBV712) Expanded Access ProtocolDBV Technologies · Peanut AllergyNo longer availableDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2019ActualPhase 3NCT03013517Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in ChildrenDBV Technologies · Peanut AllergyActive, not recruitingDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2018ActualPhase 1NCT03035370Viaskin Pertussis Vaccine TrialDBV Technologies · Whooping CoughCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2018ActualPhase 1NCT03352726A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic SubjectsDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2012ActualPhase 1NCT01170286Safety of Epicutaneous Immunotherapy for the Treatment of Peanut AllergyDBV Technologies · Peanut AllergyCompletedDBVTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2015ActualPhase 2NCT01197053Epicutaneous Immunotherapy in Peanut Allergy in ChildrenAssistance Publique - Hôpitaux de Paris · Peanut AllergyCompletedDBVTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2017ActualPhase 2NCT02579876Milk Patch for Eosinophilic EsophagitisChildren's Hospital of Philadelphia · Eosinophilic EsophagitisCompletedDBVTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner